Bilateral Intracranial Beta Activity During Forced and Spontaneous Movements in a 6-OHDA Hemi-PD Rat Model.
6-hydroxydopamine
Hemi Parkinson’s
animal model
beta oscillation
biomarker
deep brain stimulation
local field potential
neuroprosthetic
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
04
2021
accepted:
20
07
2021
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
31
8
2021
Statut:
epublish
Résumé
Cortico-basal ganglia beta oscillations (13-30 Hz) are assumed to be involved in motor impairments in Parkinson's Disease (PD), especially in bradykinesia and rigidity. Various studies have utilized the unilateral 6-hydroxydopamine (6-OHDA) rat PD model to further investigate PD and test novel treatments. However, a detailed behavioral and electrophysiological characterization of the model, including analyses of popular PD treatments such as DBS, has not been documented in the literature. We hence challenged the 6-OHDA rat hemi-PD model with a series of experiments (i.e., cylinder test, open field test, and rotarod test) aimed at assessing the motor impairments, analyzing the effects of Deep Brain Stimulation (DBS), and identifying under which conditions excessive beta oscillations occur. We found that 6-OHDA hemi-PD rats presented an impaired performance in all experiments compared to the sham group, and DBS could improve their overall performance. Across all the experiments and behaviors, the power in the high beta band was observed to be an important biomarker for PD as it showed differences between healthy and lesioned hemispheres and between 6-OHDA-lesioned and sham rats. This all shows that the 6-OHDA hemi-PD model accurately represents many of the motor and electrophysiological symptoms of PD and makes it a useful tool for the pre-clinical testing of new treatments when low β (13-21 Hz) and high β (21-30 Hz) frequency bands are considered separately.
Identifiants
pubmed: 34456673
doi: 10.3389/fnins.2021.700672
pmc: PMC8397450
doi:
Types de publication
Journal Article
Langues
eng
Pagination
700672Informations de copyright
Copyright © 2021 Mottaghi, Kohl, Biemann, Liebana, Montaño Crespo, Buchholz, Wilson, Klaus, Uchenik, Münkel, Schmidt and Hofmann.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Neurosci Methods. 2009 Mar 30;178(1):10-4
pubmed: 19041892
Brain Res. 1991 Apr 26;547(1):152-61
pubmed: 1677608
Front Neural Circuits. 2015 Jul 06;9:31
pubmed: 26217192
Neuroscience. 2017 Feb 20;343:240-249
pubmed: 27956068
Cereb Cortex. 2009 Jul;19(7):1616-30
pubmed: 18996909
J Vis Exp. 2015 Feb 06;(96):e52434
pubmed: 25742564
Brain. 2002 Jul;125(Pt 7):1558-69
pubmed: 12077005
Exp Neurol. 2006 Jan;197(1):244-51
pubmed: 16289053
Zhonghua Yi Xue Za Zhi. 2011 Feb 1;91(5):291-5
pubmed: 21419000
eNeuro. 2019 Oct 22;6(5):
pubmed: 31540998
Exp Neurol. 2005 Jul;194(1):66-75
pubmed: 15899244
J Neurophysiol. 2010 Aug;104(2):911-21
pubmed: 20505125
Neuroscience. 2008 Jan 24;151(2):386-95
pubmed: 18063484
J Neurosci. 2008 Jun 11;28(24):6165-73
pubmed: 18550758
J Am Pharm Assoc Am Pharm Assoc. 1957 Mar;46(3):208-9
pubmed: 13502156
Mov Disord. 2020 Apr;35(4):555-561
pubmed: 32039501
J Neural Transm Suppl. 2006;(70):27-30
pubmed: 17017505
Mov Disord. 2006 Oct;21(10):1566-77
pubmed: 16830313
J Neurophysiol. 1995 Oct;74(4):1800-5
pubmed: 8989416
Eur J Pharmacol. 1968 Dec;5(1):107-10
pubmed: 5718510
Brain. 2002 Jun;125(Pt 6):1196-209
pubmed: 12023310
Front Neurosci. 2017 Oct 10;11:564
pubmed: 29066947
J Vis Exp. 2014 Jul 16;(89):
pubmed: 25077449
P T. 2015 Aug;40(8):504-32
pubmed: 26236139
Neurosci Biobehav Rev. 2016 Jun;65:63-94
pubmed: 27026638
Exp Neurol. 2004 Oct;189(2):369-79
pubmed: 15380487
Nature. 1999 Aug 12;400(6745):677-82
pubmed: 10458164
Eur J Neurosci. 2005 Mar;21(5):1413-22
pubmed: 15813951
J Pharmacol Methods. 1991 Sep;26(2):149-59
pubmed: 1943125
Parkinsons Dis. 2010 Dec 20;2011:658083
pubmed: 21209719
J Neurosci. 2001 Feb 1;21(3):1033-8
pubmed: 11157088
J Neurophysiol. 2014 May;111(10):1949-59
pubmed: 24554786
J Neurosci. 2008 Mar 19;28(12):3008-16
pubmed: 18354004
Behav Brain Res. 2003 Feb 17;139(1-2):105-13
pubmed: 12642181
J Neurosci. 2002 Sep 15;22(18):7850-5
pubmed: 12223537
Ann Neurol. 2013 Sep;74(3):449-57
pubmed: 23852650
J Parkinsons Dis. 2018;8(s1):S3-S8
pubmed: 30584159
J Neurosci. 2015 Apr 29;35(17):6918-30
pubmed: 25926466
Front Hum Neurosci. 2019 May 28;13:163
pubmed: 31191273
Neurotherapeutics. 2019 Jan;16(1):105-118
pubmed: 30607748
Neuroimage. 2013 Mar;68:203-13
pubmed: 23247184
Exp Neurol. 2005 Jul;194(1):212-20
pubmed: 15899258
Behav Brain Res. 2005 Jul 1;162(1):1-10
pubmed: 15922062
Exp Neurol. 2013 Jul;245:52-9
pubmed: 22921537